GlaxoSmithKline PLC (GSK): Price and Financial Metrics

GlaxoSmithKline PLC (GSK)

Today's Latest Price: $41.70 USD

0.05 (0.12%)

Updated Jun 5 4:10pm

Add GSK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

GSK Stock Summary

  • GSK has a market capitalization of $112,237,681,516 -- more than approximately 98.37% of US stocks.
  • Glaxosmithkline Plc's stock had its IPO on July 9, 1986, making it an older stock than 92.35% of US equities in our set.
  • The volatility of Glaxosmithkline Plc's share price is greater than that of merely 3.62% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to GSK, based on their financial statements, market capitalization, and price volatility, are IBM, DHR, MMM, SNY, and TXN.
  • Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to
GSK Daily Price Range
GSK 52-Week Price Range

GSK Stock Price Chart More Charts

GSK Price/Volume Stats

Current price $41.70 52-week high $48.25
Prev. close $41.65 52-week low $31.43
Day low $41.62 Volume 2,778,969
Day high $42.07 Avg. volume 4,352,618
50-day MA $40.70 Dividend yield 4.46%
200-day MA $42.71 Market Cap 104.61B

GlaxoSmithKline PLC (GSK) Company Bio

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company’s wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.

GSK Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for GSK, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Glaxosmithkline Plc ranked in the 33th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Glaxosmithkline Plc, consider:

  • GSK's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 32.8% of tickers in our DCF set.
  • The weighted average cost of capital for the company is 8. This value is greater than only 22.7% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Glaxosmithkline Plc? See COO, IQV, DXCM, ZTS, and HAE.

GSK Latest News Stream

Event/TimeNews Detail
Loading, please wait...

GSK Latest Social Stream

Loading social stream, please wait...

View Full GSK Social Stream

Latest GSK News From Around the Web

Below are the latest news stories about Glaxosmithkline Plc that investors may wish to consider to help them evaluate GSK as an investment opportunity.

AstraZeneca blood cancer drug shows signs of helping COVID-19 patients

AstraZeneca's cancer drug Calquence has shown initial signs of helping hospitalised COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection. Results from the preliminary research involving 19 patients, which was backed by the United States National Institutes of Health, encouraged the British drugmaker to explore the drug's new use in a wider clinical trial announced in April. Eleven patients had been on oxygen when they started the 10-14 day Calquence course and eight of them could afterwards be discharged, breathing independently, according to results in a paper co-authored by Astra's head of oncology research, Jose Baselga.

Yahoo | June 5, 2020

Antibody Drugs Could Help Curb the Pandemic. What Investors Need to Know.

For investors, news on their progress could cause some drug stocks to be volatile. Among antibody developers, Vir Biotechnology has the most to gain.

Yahoo | June 5, 2020

Gates Pledges $1.6 Billion for Vaccines. What That Means for Covid-19 and Other Diseases.

The Bill and Melinda Gates Foundation is pledging $1.6 billion to a global organization that provides vaccines to children in the poorest countries.

Yahoo | June 4, 2020

GlaxoSmithKline’s Promising Drug Pipeline Should Drive the Stock Higher

GlaxoSmithKline’s stock is worth the attention for drug developments that aren’t yet factored into its value. Its trial of Cabotegravir, a regular injection to prevent HIV infection, has found early success.

Yahoo | June 4, 2020

2 FTSE 100 dividend stocks that I'd buy for income during the stock market crash - The Motley Fool UK

GlaxoSmithKline and Severn Trent are great FTSE 100 dividend stocks in the eyes of Jonathan Smith, as he explains in more detail.

The Motley Fool UK | June 3, 2020

Read More 'GSK' Stories Here

GSK Price Returns

1-mo 1.10%
3-mo -0.52%
6-mo -6.40%
1-year 9.74%
3-year 10.45%
5-year 25.63%
YTD -9.11%
2019 29.12%
2018 13.70%
2017 -3.03%
2016 -1.10%
2015 -0.27%

GSK Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8967 seconds.